Effect of the angiotensin II receptor antagonist losartan on uric acid and oxypurine metabolism in healthy subjects

被引:33
作者
Hamada, T [1 ]
Hisatome, I [1 ]
Kinugasa, Y [1 ]
Matsubara, K [1 ]
Shimizu, H [1 ]
Tanaka, H [1 ]
Furuse, M [1 ]
Sonoyama, K [1 ]
Yamamoto, Y [1 ]
Ohtahara, A [1 ]
Igawa, O [1 ]
Shigemasa, C [1 ]
Yamamoto, T [1 ]
机构
[1] Tottori Univ Hosp, Dept Cardiovasc Med, Yonago, Tottori 6838504, Japan
关键词
antihypertensive agents; urate metabolites; urinary excretion; healthy volunteers;
D O I
10.2169/internalmedicine.41.793
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective The acute effects of the angiotensin II receptor antagonist losartan on uric acid and oxypurine metabolism were evaluated. Methods Losartan (50 mg) was administered orally to 6 healthy males. Blood and urine samples for uric acid and oxypurine were collected before and up to 6 hours after losartan administration. The same examinations were performed later using enalapril (5 mg). Results Losartan decreased the serum uric acid concentration (from 5.9+/-0.9 to 5.2+/-1.0 mg/dl) and increased its fractional clearance, which reached a maximum after 2 hours, while enalapril did not. Losartan also induced an increase in the plasma concentration of hypoxanthine, peaking in the fourth hour, and a decrease in its urinary clearance, while the plasma xanthine concentration and its urinary clearance were unchanged. The extent of uric acid excretion was much greater than that of the oxypurines. Conclusions Losartan, which has a high affinity for the urate/anion exchanger, has a transient uricosuric effect. Our data indicate that losartan induces a significant decrease in the urinary excretion of hypoxanthine without changes in xanthine.
引用
收藏
页码:793 / 797
页数:5
相关论文
共 14 条
[1]   Renal effects of angiotensin II receptor blockade in normotensive subjects [J].
Burnier, M ;
RochRamel, F ;
Brunner, HR .
KIDNEY INTERNATIONAL, 1996, 49 (06) :1787-1790
[2]  
Edwards RM, 1996, J PHARMACOL EXP THER, V276, P125
[3]   FELODIPINE - A REVIEW OF THE PHARMACOLOGY AND THERAPEUTIC USE OF THE EXTENDED RELEASE FORMULATION IN OLDER PATIENTS [J].
FAULDS, D ;
SORKIN, EM .
DRUGS & AGING, 1992, 2 (05) :374-388
[4]   EFFICACY AND MODE OF ACTION OF MANIDIPINE - A NEW CALCIUM-ANTAGONIST [J].
IIMURA, O ;
SHIMAMOTO, K .
AMERICAN HEART JOURNAL, 1993, 125 (02) :635-641
[5]  
LEARY WP, 1985, LANCET, V1, P1277
[6]  
NAKASHIMA M, 1992, EUR J CLIN PHARMACOL, V42, P333
[7]  
NAVIS GJ, 1985, LANCET, V2, P156
[8]   Effect of eprosartan and losartan on uric acid metabolism in patients with essential hypertension [J].
Puig, JG ;
Mateos, F ;
Buño, A ;
Ortega, R ;
Rodriguez, F ;
Dal-Ré, R .
JOURNAL OF HYPERTENSION, 1999, 17 (07) :1033-1039
[9]  
RochRamel F, 1997, J PHARMACOL EXP THER, V280, P839
[10]   Renal effects of angiotensin I-receptor blockade and angiotensin convertase inhibition in man [J].
Schmitt, F ;
Natov, S ;
Martinez, F ;
Lacour, B ;
Hannedouche, TP .
CLINICAL SCIENCE, 1996, 90 (03) :205-213